Subpopulations	Value	Change vector	Risk factors	Presumptive reason
CD3+	abs	↑	Favorable tumor localization	Clonal proliferation of T cells after antigen recognition on APC
CD3+ HLADR+	%	↑	ALL patients	Effective presentation of tumor antigens to T-lymphocytes
CD8+ HLADR+	%	↑	ALL patients	Effective presentation of tumor antigens to cytotoxic T-lymphocytes
CD5+	abs	↑	Favorable tumor localization	Favorable prognostic factor (?)
CD3+ CD2+	abs	↑	Favorable localization	Active T cell penetration in BM
CD3+ CD28+	%	↑	Parameningeal localization of RMS	Efficient antigen presentation with clonal proliferation and accumulation of CD3+CD28+
CD3+ CD28+	%	↓	Alveolar RMS	Anergy of T-lymphocytes, tumor evasion from immune surveillance
CD3+ CD56+	%	Not changed	All groups	Low immunogenicity of RMS
CD3+ CD56+	abs	Not changed	All groups	Low immunogenicity of RMS
CD3+ CD4+	%	↓	Unfavorable localization	Inhibition of the proliferation of T-helpers or “tumor counterattack”
CD3+ CD4+	%	↓	Alveolar variant
Leu8+ CD4+	%	↓	All RMS patients	Immunodeficiency in patients with RMS
αβTCR	abs	↑	Favorable localization of the primary tumor	Favorable prognostic factor (?)
γδTCR	abs	↑	Favorable localization of the primary tumor	Favorable prognostic factor (?)
γδTCR	%	↑	All RMS patients	Containing the spread of RMS
CD19+ CD5+	abs	↑	Favorable localization	Influence of RMS on the humoral link of immunity